These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11152294)

  • 61. Conformations and receptor activity of desmopressin analogues, which contain gamma-turn mimetics or a psi[CH(2)O] isostere.
    Hedenström M; Yuan Z; Brickmann K; Carlsson J; Ekholm K; Johansson B; Kreutz E; Nilsson A; Sethson I; Kihlberg J
    J Med Chem; 2002 Jun; 45(12):2501-11. PubMed ID: 12036358
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin.
    Manning M; Lammek B; Bankowski K; Seto J; Sawyer WH
    J Med Chem; 1985 Oct; 28(10):1485-91. PubMed ID: 4045923
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Conformational aspects of differences in requirements for oxytocin and vasopressin receptors.
    Oldziej S; Ciarkowski J; Liwo A; Shenderovich MD; Grzonka Z
    J Recept Signal Transduct Res; 1995; 15(1-4):703-13. PubMed ID: 8903974
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Fluorescence study of neurohypophyseal hormones and their analogues. Distance distributions in a series of arginine-vasopressin analogues.
    Wiczk W; Lankiewicz L; Kasprzykowski F; Ołdziej S; Szmaciński H; Lakowicz JR; Grzonka Z
    Eur Biophys J; 1997; 26(2):183-93. PubMed ID: 9232846
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Potent vasopressin antagonists lacking the proline residue at position 7.
    Ali FE; Bryan W; Chang HL; Huffman WF; Moore ML; Heckman G; Kinter LB; McDonald J; Schmidt D; Shue D
    J Med Chem; 1986 Jun; 29(6):984-8. PubMed ID: 2940368
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.
    Manning M; Kruszynski M; Bankowski K; Olma A; Lammek B; Cheng LL; Klis WA; Seto J; Haldar J; Sawyer WH
    J Med Chem; 1989 Feb; 32(2):382-91. PubMed ID: 2913298
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Gastrointestinal absorption and plasma clearance rates of [D-Arg8]vasopressin analogues in the rat.
    Lundin S; Folkesson HG; Pierzynovski SG; Bengtsson HI
    Peptides; 1994; 15(5):809-14. PubMed ID: 7984498
    [TBL] [Abstract][Full Text] [Related]  

  • 68. C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.
    Manning M; Misicka A; Olma A; Klis WA; Bankowski K; Nawrocka E; Kruszynski M; Kolodziejczyk A; Cheng LL; Seto J
    J Med Chem; 1987 Dec; 30(12):2245-52. PubMed ID: 2960812
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays.
    Chan WY; Wo NC; Stoev ST; Cheng LL; Manning M
    Exp Physiol; 2000 Mar; 85 Spec No():7S-18S. PubMed ID: 10795902
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The effects of N-terminal part modification of arginine vasopressin analogues with 2-aminoindane-2-carboxylic acid: a highly potent V2 agonist.
    Kowalczyk W; Sobolewski D; Prahl A; Derdowska I; Borovicková L; Slaninová J; Lammek B
    J Med Chem; 2007 Jun; 50(12):2926-9. PubMed ID: 17500550
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptors.
    Ala Y; Morin D; Mahé E; Cotte N; Mouillac B; Jard S; Barberis C; Tribollet E; Dreifuss JJ; Sawyer WH; Wo NC; Chan WY; Kolodziejczyk AS; Cheng LL; Manning M
    Eur J Pharmacol; 1997 Jul; 331(2-3):285-93. PubMed ID: 9274991
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Structure-activity relationships of gamma-MSH analogues at the human melanocortin MC3, MC4, and MC5 receptors. Discovery of highly selective hMC3R, hMC4R, and hMC5R analogues.
    Balse-Srinivasan P; Grieco P; Cai M; Trivedi D; Hruby VJ
    J Med Chem; 2003 Nov; 46(23):4965-73. PubMed ID: 14584947
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Biologically active analogues of arginine vasopressin containing conformationally restricted dipeptide fragments.
    Lammek B; Czaja M; Derdowska I; Lempicka E; Sikora P; Szkróbka W; Trzeciak HI
    J Pept Res; 1998 Feb; 51(2):149-54. PubMed ID: 9516050
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
    Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G
    Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A new series of photoactivatable and iodinatable linear vasopressin antagonists.
    Carnazzi E; Aumelas A; Barberis C; Guillon G; Seyer R
    J Med Chem; 1994 Jun; 37(12):1841-9. PubMed ID: 8021923
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Conformation of desmopressin, an analogue of the peptide hormone vasopressin, in aqueous solution as determined by NMR spectroscopy.
    Walse B; Kihlberg J; Drakenberg T
    Eur J Biochem; 1998 Mar; 252(3):428-40. PubMed ID: 9546658
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Conformational studies of cyclic enkephalin analogues with L- or D-proline in position 3.
    Malicka J; Groth M; Czaplewski C; Wiczk W; Liwo A
    Biopolymers; 2002 Apr; 63(4):217-31. PubMed ID: 11807749
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin.
    Manning M; Olma A; Klis WA; Kolodziejczyk AM; Seto J; Sawyer WH
    J Med Chem; 1982 Jan; 25(1):45-50. PubMed ID: 7086821
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A single residue (arg46) located within the N-terminus of the V1a vasopressin receptor is critical for binding vasopressin but not peptide or nonpeptide antagonists.
    Hawtin SR; Wesley VJ; Parslow RA; Simms J; Miles A; McEwan K; Wheatley M
    Mol Endocrinol; 2002 Mar; 16(3):600-9. PubMed ID: 11875119
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Novel strategies for the design of receptor-selective vasopressin analogues: Aib-substitution and retro-inverso transformation.
    Howl J; Prochazka Z; Wheatley M; Slaninová J
    Br J Pharmacol; 1999 Oct; 128(3):647-52. PubMed ID: 10516644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.